Engineering Immunoreceptor and Cytokine Signaling for Therapeutics

 Saturday, May 7, 2022     8:00 AM – 10:00 AM ET     Oregon Ballroom 201

Engineering Immunoreceptor and Cytokine Signaling for Therapeutics

Chairs

• Ingunn Stromnes, Univ. of Minnesota
• Carl Ware, Sanford Burnham Prebys Med. Discovery Inst.

Speakers

• Nina Beryl Horowitz, Stanford Univ., Overcoming barriers to solid tumor immunotherapy using natural killer cell therapies designed to mimic intraepithelial group 1 innate lymphoid cells
• Meagan R. Rollins, Univ. of Minnesota Med. Sch., Adoptive transfer of Trac-targeted T cell receptor engineered T cells with defective Tgfbr2 signaling promotes pancreatic cancer eradication
• Karen Michelle Christie, Univ. of Delaware, Directing T cell alloreactivity against solid tumors through tumor antigen dependent TCR expression
• Zachariah Peter Tritz, Mayo Clin. Grad. Sch. of BioMed. Sci., Combination of αPD-1 and extended half-life IL-2 is effective against the GL261 glioma and uniquely reverses GBM-associated immunosuppression
• Travis J. Shute, UT Hlth. San Antonio, Glycolipid-loaded nanoparticle immunotherapy cooperates with checkpoint inhibitors to harness iNKT cells for tumor control
• Aliyah Brianne Silver, Johns Hopkins Bloomberg Sch. of Public Hlth., A tumor-targeted cytokine/antibody fusion protein to stimulate anti-cancer immunity
• Kyle Alexander Romine, Oregon Hlth. and Sci. Univ., BET inhibitors synergize with anti-PD1 by rescuing TCF1+ progenitor exhausted T cells in acute myeloid leukemia
• Hien T. Huynh, Univ. of Missouri Columbia, Dissecting molecular mechanisms underlying T cell co-potentiation when targeting the TCR/CD3 complex with anti-CD3 Fab fragments